Home And Locally Observed - Tracking (HALO-Trak)

Last updated: July 24, 2023
Sponsor: University College, London
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neoplasms

Metastatic Cancer

Treatment

Halo Wearable data device

Clinical Study ID

NCT05971277
150745
312296
  • Ages > 18
  • All Genders

Study Summary

The goal of this observational study is to collect biometric, HRQoL, immune response and genomic data continuously and intermittently during and after chemo or immunotherapy for the generation of a complex dataset using a platform which can aggregate different types of data collected over a time period and, to test the potential for analysis within and across data sets with linkage to clinical outcomes. The framework will have capabilities to integrate data from electronic medical records (EMRs) such as Epic, as well as digital streams including sensor, genomic, imaging and pathology. Such a platform can realise the potential for machine learning (ML) methodologies to address important cancer outcomes.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • ● A diagnosis of a metastatic or haematological cancer undergoing systemic therapy
  • Undergoing at least 1 planned cycle of chemotherapy or immunotherapy, accordingto standard of care practices.
  • Ability to understand and the willingness to sign a written informed consent.
  • Able to ambulate without assistance or walking aid.
  • Have an Android or iOS phone and willing to download the Ethera app

Exclusion

Exclusion Criteria:

  • ● Physical disabilities that preclude daily walking
  • Inability to provide informed consent.
  • Unable to use and operate the Ethera Health Monitoring Smartphone App. (Apple orAndroid)
  • Medical or psychiatric condition which in the investigator's opinion would affectthe successful completion of the study.

Study Design

Total Participants: 200
Treatment Group(s): 1
Primary Treatment: Halo Wearable data device
Phase:
Study Start date:
January 30, 2023
Estimated Completion Date:
April 01, 2026

Study Description

The Investigators overarching aim is to determine the relationship between measures of physical performance status including heart rate and steps, health related quality of life (HRQoL) and genomic and immunogenomic phenotype on cancer outcomes in patients receiving chemotherapy or immunotherapy for haematological or metastatic cancer including renal (papillary, and RCC), breast, prostate, and other solid tumours. The primary objective is to test the feasibility of integrating diverse data streams (genomic, HR QoL and biometric) on a novel platform, capable of integrating data streams thus generating complex datasets for analyses using machine learning methodologies.

Secondary objectives will be to conduct exploratory analysis assessing the relationship between individual and combined data types and cancer outcomes.

Analysis using existing and novel computational models will be applied to the data to events in the acute and chronic setting that are common in patients diagnosed with cancer undergoing systemic therapy such as chemotherapy and immunotherapy. The outputs from this study will help inform future studies and trials designed to inform patients about their health status during cancer therapy

Connect with a study center

  • UCL London

    London, W1W 7TY
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.